English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Supply chain risk management can help companies detect potential hazards, mitigate potential risks, and thereby increase supply chain efficiency. The biopharmaceutical industry in Iran has a generic-based pharmerging market. Therefore, identifying risks associated with the supply chain of these drugs can significantly boost the possibility of success of biopharmaceutical companies. This study is designed to determine the supply chain risk factors of biopharmaceuticals companies in Iran. Methods: The current research work is a qualitative-quantitative study. A systematic review and interview with experts (n=14) were conducted to identify potential supply chain risks in the biopharmaceutical industries. To determine the significance of identified risks, Fuzzy screening method was employed to collect the opinions of experts (n=16) in the biopharmaceutical industries. Results: By systematic review and interviews with the biopharmaceutical industry experts, 100 potential risks in the biopharmaceutical industry supply chain were identified. These risks were divided into two general categories namely macro and micro risks. Based on experts’judgment, 77 out of 100 identified risks were eliminated and 23 significant risks were determined. The most important risks are: Ministry of health (as regulatory body) conflict of interest, US sanctions, lack of domestic suppliers of essential materials, pseudo-productivity, and money transfer related to bank’s sanctions. Conclusion: Due to the multitude of present risks and the impossibility of controlling all these risks, it is recommended that managers and producers focus more on controlling the identified significant risks.

Risk Factors of Supply Chain in Biopharmaceutical Companies in Iran